{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Evolocumab",
    "query": {
      "intervention": "Evolocumab"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 70,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Evolocumab&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T07:58:47.537Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05641753",
      "title": "Cholesterol Lowering and Residual Risk in Diabetes, Type 1",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "Evolocumab Cartridge",
          "type": "DRUG"
        },
        {
          "name": "Atorvastatin Calcium Tablets",
          "type": "DRUG"
        },
        {
          "name": "Ezetimibe Tablets",
          "type": "DRUG"
        },
        {
          "name": "18F-FDG",
          "type": "DRUG"
        },
        {
          "name": "Angiocatheter 20IV",
          "type": "DEVICE"
        },
        {
          "name": "J-Wire",
          "type": "DEVICE"
        },
        {
          "name": "GlycoCheck Glycocalyx Measurement Software",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 125,
      "start_date": "2022-12-06",
      "completion_date": "2027-07-31",
      "has_results": false,
      "last_update_posted_date": "2025-12-29",
      "last_synced_at": "2026-09-02T07:58:47.537Z",
      "location_count": 4,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05641753"
    },
    {
      "nct_id": "NCT01763866",
      "title": "LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hyperlipidemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ezetimibe",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Evolocumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Ezetimibe",
          "type": "DRUG"
        },
        {
          "name": "Atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin",
          "type": "DRUG"
        },
        {
          "name": "Simvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 2067,
      "start_date": "2013-01-15",
      "completion_date": "2013-12-04",
      "has_results": true,
      "last_update_posted_date": "2022-11-08",
      "last_synced_at": "2026-09-02T07:58:47.537Z",
      "location_count": 65,
      "location_summary": "Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 58 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Carmichael",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01763866"
    },
    {
      "nct_id": "NCT02275156",
      "title": "Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hyperlipidemia",
        "Mixed Dyslipidemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 18,
      "start_date": "2014-08-19",
      "completion_date": "2014-12-19",
      "has_results": true,
      "last_update_posted_date": "2022-11-07",
      "last_synced_at": "2026-09-02T07:58:47.537Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02275156"
    },
    {
      "nct_id": "NCT03872401",
      "title": "Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Coronary Heart Disease (CHD)"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "50 Years to 79 Years"
      },
      "enrollment_count": 12301,
      "start_date": "2019-06-11",
      "completion_date": "2025-07-25",
      "has_results": true,
      "last_update_posted_date": "2026-06-25",
      "last_synced_at": "2026-09-02T07:58:47.537Z",
      "location_count": 145,
      "location_summary": "Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 127 more",
      "locations": [
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03872401"
    },
    {
      "nct_id": "NCT05152888",
      "title": "The Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV Risk",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Stable Coronary Disease"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 50,
      "start_date": "2022-03-03",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-11-04",
      "last_synced_at": "2026-09-02T07:58:47.537Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05152888"
    },
    {
      "nct_id": "NCT01375764",
      "title": "Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hyperlipidemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ezetimibe",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Evolocumab",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 160,
      "start_date": "2011-07-28",
      "completion_date": "2012-05-08",
      "has_results": true,
      "last_update_posted_date": "2022-11-07",
      "last_synced_at": "2026-09-02T07:58:47.537Z",
      "location_count": 16,
      "location_summary": "Anaheim, California • Mission Viejo, California • Westlake Village, California + 12 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "Westlake Village",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01375764"
    },
    {
      "nct_id": "NCT04189484",
      "title": "Pharmacodynamic Biomarkers to Support Biosimilar Development: PCSK9 Inhibitors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Subjects",
        "Pharmacokinetics",
        "Pharmacodynamics"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Alirocumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Food and Drug Administration (FDA)",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 72,
      "start_date": "2020-01-07",
      "completion_date": "2021-04-07",
      "has_results": true,
      "last_update_posted_date": "2024-04-22",
      "last_synced_at": "2026-09-02T07:58:47.537Z",
      "location_count": 1,
      "location_summary": "West Bend, Wisconsin",
      "locations": [
        {
          "city": "West Bend",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04189484"
    },
    {
      "nct_id": "NCT03175367",
      "title": "Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Evinacumab",
          "type": "DRUG"
        },
        {
          "name": "Matching placebo",
          "type": "DRUG"
        },
        {
          "name": "Background Lipid Modifying Therapy (LMT)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 272,
      "start_date": "2017-11-10",
      "completion_date": "2020-12-14",
      "has_results": true,
      "last_update_posted_date": "2023-02-10",
      "last_synced_at": "2026-09-02T07:58:47.537Z",
      "location_count": 23,
      "location_summary": "Los Angeles, California • Newport Beach, California • Boca Raton, Florida + 19 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Doral",
          "state": "Florida"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03175367"
    },
    {
      "nct_id": "NCT07704918",
      "title": "Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Statins (atorvastatin, rosuvastatin, simvastatin, or pravastatin), +/- ezetimibe, +/- PCSK9 inhibitor (alirocumab, evolocumab, inclisiran)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2026-12-31",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-08-07",
      "last_synced_at": "2026-09-02T07:58:47.537Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07704918"
    },
    {
      "nct_id": "NCT03570697",
      "title": "Imaging of Coronary Plaques in Participants Treated With Evolocumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Coronary Artery Disease (CAD)"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Statin therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 164,
      "start_date": "2018-11-19",
      "completion_date": "2021-01-21",
      "has_results": true,
      "last_update_posted_date": "2022-05-03",
      "last_synced_at": "2026-09-02T07:58:47.537Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Elkhart, Indiana + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Elkhart",
          "state": "Indiana"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03570697"
    }
  ]
}